Class 1.1 new drug of Zhejiang medicine, nanofloxacin malate, entered the site for inspection this month

According to information on CFDA's website, Zhejiang Pharmaceutical (600216 SH) will enter the drug registration and production site for inspection this month According to the drug review process, the product is expected to be approved within half a year It is worth mentioning that ninofloxacin has passed the expert review in September last year The company's personnel confirmed to big smart news agency that the review feedback is optimistic and the important obstacles to approval have been removed Nanofloxacin is a new type of fluoroquinolones free drug and a high-end product of quinolones It has attracted market attention since its application It is generally believed in the industry that ninofloxacin will form a benign complementary advantage with the existing quinolones and antibiotic resistant products of Zhejiang Pharmaceutical, enrich the company's high-end antibiotic product group, improve and enrich the preparation varieties, and improve the current predicament of the decline in API revenue.